What is Clinuvel Pharmaceuticals Book Value per Share?
Clinuvel Pharmaceuticals's book value per share for the quarter that ended in Dec. 2023 was A$3.56.
During the past 12 months, Clinuvel Pharmaceuticals's average Book Value Per Share Growth Rate was 26.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 30.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 31.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 29.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Clinuvel Pharmaceuticals was 48.60% per year. The lowest was -31.90% per year. And the median was 1.50% per year.
During the past 13 years, the highest P/B Ratio of Clinuvel Pharmaceuticals was 46.78. The lowest was 2.62. And the median was 13.09.
Clinuvel Pharmaceuticals Book Value per Share Historical Data
The historical data trend for Clinuvel Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Clinuvel Pharmaceuticals Book Value per Share Chart
Competitive Comparison of Clinuvel Pharmaceuticals's Book Value per Share
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's PB Ratio falls into.
Clinuvel Pharmaceuticals Book Value per Share Calculation
Clinuvel Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Clinuvel Pharmaceuticals (ASX:CUV) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Clinuvel Pharmaceuticals Book Value per Share Related Terms
Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Clinuvel Pharmaceuticals (ASX:CUV) Business Description
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:CUV has been successfully added to your 